PEARSON TIMOTHY R 4
4 · Ra Pharmaceuticals, Inc. · Filed Apr 3, 2020
Insider Transaction Report
Form 4
PEARSON TIMOTHY R
Director
Transactions
- Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−15,000→ 0 totalExercise: $19.88Exp: 2029-06-11→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−15,000→ 0 totalExercise: $9.90Exp: 2028-06-28→ Common Stock (15,000 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−22,857→ 0 totalExercise: $2.87Exp: 2026-03-10→ Common Stock (22,857 underlying) - Disposition to Issuer
Stock Option (Right to Buy)
2020-04-02−15,000→ 0 totalExercise: $22.37Exp: 2027-06-20→ Common Stock (15,000 underlying)
Footnotes (2)
- [F1]Disposed of pursuant to an Agreement and Plan of Merger (the "Merger Agreement"), dated October 9, 2019, among Ra Pharmaceuticals, Inc. (the " Issuer"), UCB S.A., and Franq Merger Sub, Inc., providing for the merger (the "Merger") of Franq Merger Sub, Inc. into the Issuer, in exchange for a cash payment of $48.00 per share.
- [F2]Pursuant to the Merger Agreement, at the effective time of the Merger, each option, whether vested or unvested, was cancelled in exchange for a cash payment equal to: (a) the number of shares of Issuer common stock underlying the option, multiplied by (b) the excess of $48.00 over the per share exercise price of such option.